ClinicalTrials.gg

Program

BMS-986310

Also written as “ONO-4578”.

Its studies are mostly in Stomach Neoplasms · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms, led by 2 companies.

Furthest: phase 3, since Sep 9, 20266 company-led studies, 4 open or runningNext primary completion: Feb 15, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ono Pharmaceutical54 open or runningphase 3since Sep 9, 2026Mar 17, 2017Feb 15, 2028phase 2 · NCT06948448
Bristol-Myers Squibb10 open or runningphase 1since Aug 30, 2018Aug 30, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 17, 2017First study: phase 1 study in Advanced or Metastatic Solid TumorsNew to Ono PharmaceuticalOno Pharmaceutical · NCT03155061 · 183 enrolled · Japan
  2. Aug 30, 2018Bristol-Myers Squibb's first study: phase 1 study in Advanced CancerNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT03661632 · 27 enrolled · United States, Belgium, Canada
  3. Jan 23, 2024Phase 2 study in Stomach NeoplasmsOno Pharmaceutical · NCT06256328 · 226 enrolled · Japan, South Korea, Taiwan
  4. Aug 1, 2024Phase 1 study in Carcinoma, Non-Small-Cell LungOno Pharmaceutical · NCT06542731 · 42 enrolled · Japan
  5. Apr 21, 2025Phase 2 study in Colorectal NeoplasmsOno Pharmaceutical · NCT06948448 · 144 planned · United States, Canada, France and more
  6. Sep 9, 2026Phase 3 study in Stomach NeoplasmsPhase 3 reachedOno Pharmaceutical · NCT07818070 · 600 planned

Ahead

  1. Feb 15, 2028Primary completion: phase 2 study in Colorectal NeoplasmsOno Pharmaceutical · NCT06948448
  2. Mar 2028Primary completion: phase 1 study in Advanced or Metastatic Solid TumorsOno Pharmaceutical · NCT03155061
  3. Jan 2031Primary completion: phase 3 study in Stomach NeoplasmsOno Pharmaceutical · NCT07818070

TargetBeta

PTGER4 →read by rule
“An orally bioavailable antagonist of the prostaglandin E2 receptor subtype 4 (PTGER4; EP4), ”NCIt, by rule

Other programs on PTGER4

ProgramCompanyFurthest phaseStudies
EP4 Receptor Antagonist YY001rulechongqing-claruvis-pharmaceutical-co-ltdphase 36
EP2/EP4/DP1 Antagonist OKN4395ruleepkinphase 11

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07818070Stomach Neoplasms3Not yet recruitingOno PharmaceuticalJan 2031600
NCT06948448Colorectal Neoplasms · United States, Canada, France and more2RecruitingOno PharmaceuticalFeb 15, 2028144
NCT06542731Carcinoma, Non-Small-Cell Lung · Japan1CompletedOno PharmaceuticalOct 30, 202542
NCT06256328Stomach Neoplasms · Japan, South Korea, Taiwan2Active, not recruitingOno PharmaceuticalOct 9, 2025226
NCT03661632Advanced Cancer · United States, Belgium, Canada1CompletedBristol-Myers SquibbNov 11, 201927
NCT03155061Advanced or Metastatic Solid Tumors · Japan1Active, not recruitingOno PharmaceuticalMar 2028183

How it is read

Names in the registry

  • “ONO-4578”, 5 entries
  • “BMS-986310”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.